Supreme Court: Spouse Cannot Withdraw Consent for Mutual Divorce After Settlement Agreement || Supreme Court Suspends PC Act Sentence of Former Minister Anosh Ekka, Flags Overlapping CBI Cases || Supreme Court: Magistrate’s Probe Order Can’t be Quashed on Accused’s Defence || Delhi High Court: No Adverse Inference if Handwriting Sample Refused Without Section 73 Disclosure || J&K&L HC: Bank Officials Not Entitled to Section 197 CrPC Protection Despite Public Servant Status || Kar HC Orders CBI Probe into 53-Acre Land Acquisition, Citing Alleged Monumental Fraud & Conspiracy || Supreme Court Grants Probation to Convicts; Rules Fine-Only Cases Also Eligible || SC Disposes Plea on Allied Health Course Moratorium After NCAHP Issues 2026–27 Guideline || Supreme Court Grants Promotion Relief to Employee Denied Relaxation, Calling it Discrimination || Patna HC: Tender Lapses if Not Extended on Time & Delay Cannot be Cured by Repeated Representations

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :